Radionuclide therapy for Metastatic Prostate Cancer

for metastatic prostate cancer

  • Targeted therapy with Lutetium-PSMA for castrate-resistant metastatic prostate cancers
  • Progression-free survival of 11-14 months in patients with progressive disease resistant to all conventional therapies
  • Negligible adverse effects
  • A regular whole body FDG PET is not sufficient for prostate cancer, PSMA PET-CT is a more advanced technique
  • Most sensitive and specific scan for evaluation of prostate cancers.
  • You can do 1 single scan that can give you all the information that MRI, CT scan and bone scan together can give.
  • It gives detailed information about the prostate tumour and if it has spread to any node, organ or bone in the body. Can pick up even 3-4 mm sized nodes.
  • The scan can be done for investigation of high Sr. PSA levels to look if the patient has prostate cancer
  • If there is a high PSA level after treatment, PSMA PET is known to pick the disease regrowth earlier than any other scan available.
  • If scan is positive, then in suitable cases, patient can be given nuclear medicine therapy for prostate cancer that is spread. The results are very promising.

Did you know ?
In patients with metastatic prostate cancer, resistant to all conventional therapies, Lutetium therapy has a documented response in over 60% of patient population